Advancing Prostate Cancer Care: Integrating Guideline Updates and Patient Preferences for Optimal ADT Management of Advanced Prostate Cancer

Best Practices in Shared Decision Making: Selection of the Optimal ADT Regimen in mHSPC Based on Patient Preferences

Media formats available:

Details

Episodes

Presenters

Comments

Overview
In 2024, an estimated 300,000 individuals received a prostate cancer diagnosis in the United States. It is thus vital that oncologists stay abreast of current guideline recommendations for treatment selection in the varied clinical scenarios and monitoring testosterone levels, particularly in advanced disease. Moreover, the identification, mitigation, and management of treatment-related adverse events from ADT are critical yet often inadequately addressed. Effective management of advanced prostate cancer requires a collaborative approach involving shared decision-making between clinicians and patients. In this educational series, expert faculty review best practices for treatment of advanced prostate cancer to optimize both clinical outcomes and patient quality of life.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Faculty:
Tanya Dorff, MD, MPH
Division Chief
Genitourinary Disease Program
City of Hope
Duarte, CA
Dr. Dorff has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting fees: Astellas, AstraZeneca, Bayer, Janssen, Novartis
Research: AbbVie, Amgen, Arvinas, AstraZeneca, Gentech, Pfizer
Rana Mckay, MD
Clinical Professor
University of California San Diego
San Diego, CA
Dr. Mckay has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting fees: AstraZeneca, Atera AI, Bayer, Bristol Myers Squibb, Gentech, Pfizer
Research: Ambrx, Arcus, AstraZeneca, Aveo, Bayer, Blue Earth Diagnostics, Bristol Myers Squibb, Calithera, Caris, Daiichi Sankyo.
Reviewers/Content Planners/Authors:
- Cindy Davidson has nothing to disclose.
- Wilma Guerra has nothing to disclose.
- Brian P. McDonough, MD, FAAFP, has nothing to disclose.
Learning Objectives
After participating in this educational activity, participants should be better able to:
- Describe the importance of testosterone levels in the treatment of advanced prostate cancer using clinical trial endpoints, including monitoring treatment efficacy and the impact of testosterone recovery on quality of life
- Evaluate the efficacy and safety profiles of GnRH agonists and antagonists, both as monotherapies and in combination regimens, across different treatment settings for advanced prostate cancer
- Apply practice-changing evidence and guideline updates to inform selection of ADT to improve management of patients with advanced prostate cancer
- Employ strategies to identify, mitigate, and manage potential treatment-related adverse events in patients receiving both ADT monotherapy and combination regimens for advanced prostate cancer
- Apply a shared decision-making approach to effectively guide and facilitate treatment selection for individuals diagnosed with advanced prostate cancer based on a mutual understand of patient treatment preferences
Target Audience
This activity has been designed to meet the educational needs of medical oncologists and urologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with GU cancers.
Accreditation and Credit Designation Statements
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 0.75 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity
Global Learning Collaborative (GLC) designates this activity for 0.75 contact hour/0.075 CEUs of pharmacy contact hours.

The Universal Activity Number for this program is UAN JA0006235-0000-24-157-H01-P. This learning activity is knowledge based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 0.75 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit(s). Approval is valid until 12/20/2025. PAs should claim only the credit commensurate with the extent of their participation in the activity. with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.
Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.
Commercial Support
This activity is supported by an independent educational grant from Merck Sharp & Dohme LLC.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 12/20/2024
Expiration Date: 12/20/2025